Effects of drospirenone-ethinylestradiol and/or metformin on CD4 +CD28null T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: A randomized clinical trial

Reproductive Sciences

Volumn 20, Issue 12, 2013, Pages 1508-1517

  Moro, Francesca ^a   Morciano, Andrea ^a   Tropea, Anna ^a   Sagnella, Francesca ^a   Palla, Carola ^a   Scarinci, Elisa ^a   Ciardulli, Andrea ^a   Martinez, Daniela ^a   Familiari, Alessandra ^a   Liuzzo, Giovanna ^a   Tritarelli, Alessandra ^a   Cosentino, Nicola ^a   Niccoli, Giampaolo ^a   Crea, Filippo ^a   Lanzone, Antonio ^b   Apa, Rosanna ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

CD4+CD28null T lymphocytes; drospirenone; ethinylestradiol; metformin; polycystic ovary syndrome

Indexed keywords

ANDROGEN; DROSPIRENONE PLUS ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; METFORMIN;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CD4 CD8 RATIO; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERINSULINEMIA; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MONOTHERAPY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME;

CD4+CD28NULL T-LYMPHOCYTES; DROSPIRENONE; ETHINYLESTRADIOL; METFORMIN; POLYCYSTIC OVARY SYNDROME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANDROSTENES; ANTIGENS, CD28; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHI-SQUARE DISTRIBUTION; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; METFORMIN; POLYCYSTIC OVARY SYNDROME; REPRODUCTIVE CONTROL AGENTS; RISK FACTORS; ROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887453332     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113488444     Document Type: Article

References (56)

1. Homburg R. Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. 1996 ; 11 (1). 29-39 (Pubitemid 26047668)
2. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab. 2005 ; 90 (10). 5711-5716 (Pubitemid 41415480)
3. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 ; 19 (1). 41-47
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A.. A Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989 ; 38 (9). 1165-1174 (Pubitemid 19250404)
5. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low-grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001 ; 86 (6). 2453-2455 (Pubitemid 32545690)
6. Yildiz BO, Haznedaroǧlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002 ; 87 (8). 3871-3875 (Pubitemid 34879542)
7. Carmassi F, De Negri F, Fioriti R, et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res. 2005 ; 116 (3). 207-214 (Pubitemid 40776019)
8. Orio F, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005 ; 90 (11). 6072-6076 (Pubitemid 41606527)
9. Niccoli G, Apa R, Lanzone A, et al. CD4+CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertil Steril. 2011 ; 95 (8). 2651-2654
10. Dumitriu IE, Araguas ET, Baboonian C, Kaski JC. CD4+CD28null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res. 2009 ; 81 (1). 11-19
11. Thewissen M, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol. 2007 ; 179 (10). 6514-6523
12. Martens PB, Goronzy JJ, Schaid DJ, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997 ; 40 (6). 1060-1114
13. Vallejo AN, Weyand CM, Goronzy JJ. T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection. Trends Mol Med. 2004 ; 10 (3). 119-124 (Pubitemid 38293347)
14. Gerli R, Schillaci G, Giordano A, et al. CD4+ CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004 ; 109 (22). 2744-2748 (Pubitemid 38737922)
15. Betjes MG, de Wit EE, Weimar W. Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrol Dial Transplant. 2010 ; 25 (11). 3640-3646
16. Alber HF, Duftner C, Wanitschek M, et al. CD4+CD28-lymphocytes and the extent and severity of coronary artery disease. Int J Cardiol. 2009 ; 135 (1). 27-35
17. Giubilato S, Liuzzo G, Brugaletta S, et al. Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. Eur Heart J. 2011 ; 32 (10). 1214-1226
18. Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999 ; 100 (21). 2135-2139
19. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000 ; 101 (25). 2883-2888 (Pubitemid 30415876)
20. Liuzzo G, Biasucci LM, Trotta G, et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol. 2007 ; 50 (15). 1450-1458 (Pubitemid 47494592)
21. Moro F, Morciano A, Tropea A, et al. CD4(+)CD28(null)T lymphocyte frequency, a new marker of cardiovascular risk: relationship with polycystic ovary syndrome phenotypes. Fertil Steril. 2012 ; 98 (6). 1609-1615
22. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009 ; 30 (1). 1-50
23. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003 ; 327 (7421). 951-953
24. Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol. 2011 ; 75 (4). 520-527
25. Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol. 2008 ; 199 (6). 596-609
26. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril. 2010 ; 94 (5). 1793-1798
27. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception. 1999 ; 42 (6). 611-619
28. Hillard PJ. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents. Endocrinol Metab Clin North Am. 2005 ; 34 (3). 707-723 (Pubitemid 41112094)
29. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab. 2003 ; 88 (1). 148-156 (Pubitemid 36115157)
30. Guido M, Romualdi D, Giuliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab. 2004 ; 89 (6). 2817-2823 (Pubitemid 38766371)
31. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinylestradiol in the long-term treatment of hirsutism. Fertil Steril. 2006 ; 85 (2). 436-440 (Pubitemid 43170919)
32. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001 ; 285 (15). 1987-1991 (Pubitemid 32366951)
33. Ciampelli M, Leoni F, Cucinelli F, et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab. 2005 ; 90 (3). 1398-1406 (Pubitemid 40463995)
34. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961 ; 21: 1440-1447
35. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005 ; 141 (3). 333-338 (Pubitemid 40365449)
36. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009 ; 15 (4). 477-488
37. Liuzzo G, Vallejo AN, Kopecky SL, et al. Molecular fingerprint of interferon-gamma signaling in unstable angina. Circulation. 2001 ; 103 (11). 1509-1514 (Pubitemid 32226257)
38. Nakajima T, Schulte S, Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002 ; 105 (5). 570-575 (Pubitemid 34123430)
39. Pryshchep S, Sato K, Goronzy JJ, Weyand CM. T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circ Res. 2006 ; 98 (9). 1168-1176 (Pubitemid 43948103)
40. Zal B, Kaski JC, Arno G, et al. Heat-shock protein 60-reactive CD4+ CD28null T cells in patients with acute coronary syndromes. Circulation. 2004 ; 109 (10). 1230-1235 (Pubitemid 38372781)
41. Zal B, Kaski JC, Akiyu JP, et al. Differential pathways govern CD4+ CD28-T cell proinflammatory and effector responses in patients with coronary artery disease. J Immunol. 2008 ; 181 (8). 5233-5241
42. Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril. 2011 ; 96 (2). 501-504
43. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood. 2003 ; 101 (9). 3543-3549 (Pubitemid 36857940)
44. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of CD28 expression by TNF-α. J Immunol. 2001 ; 167 (6). 3231-3238
45. Esposito K, Nappo F, Marfella F, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Role of oxidative stress. Circulation. 2002 ; 106 (16). 2067-2072 (Pubitemid 35192812)
46. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009 ; 94 (9). 3171-3182
47. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products. Sparking the development of diabetic vascular injury. Circulation. 2006 ; 114 (6). 597-605 (Pubitemid 44199649)
48. Brugaletta S, Biasucci LM, Pinnelli M, et al. A novel anti inflammatory effect of statin: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina. Heart. 2006 ; 92 (2). 249-250 (Pubitemid 43131971)
49. Rizzello V, Liuzzo G, Brugaletta S, Rebuzzi AG, Biasucci LM, Crea F. Modulation of CD4+CD28null T lymphocytes by tumor necrosis factor-α blockade in patients with unstable angina. Circulation. 2006 ; 113 (19). 2272-2277 (Pubitemid 43947972)
50. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010 ; 162 (2). 193-212
51. Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Ethinyl estradiol- drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013 ; 78 (3). 379-384
52. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep. 2003 ; 5 (2). 106-109 (Pubitemid 38898939)
53. Kraus D, Jäger J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005 ; 37 (7). 455-459 (Pubitemid 41081228)
54. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so called hyperthecosis. Obstet Gynecol Surv. 1982 ; 37 (2). 59-77 (Pubitemid 12104168)
55. Nelson VL, Legro RS, Strauss JF III, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999 ; 13 (6). 946-957 (Pubitemid 30645312)
56. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 ; 62 (1). 29-38